ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 98 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $1,579,000 | +276.8% | 263,595 | +365.3% | 0.00% | +100.0% |
Q4 2018 | $419,000 | -70.1% | 56,651 | -41.3% | 0.00% | 0.0% |
Q3 2018 | $1,402,000 | +45.3% | 96,580 | +99.8% | 0.00% | 0.0% |
Q2 2018 | $965,000 | +30.1% | 48,336 | +14.2% | 0.00% | 0.0% |
Q1 2018 | $742,000 | -28.5% | 42,335 | +0.6% | 0.00% | 0.0% |
Q4 2017 | $1,038,000 | +3.6% | 42,099 | +8.4% | 0.00% | 0.0% |
Q3 2017 | $1,002,000 | +0.5% | 38,826 | +5.6% | 0.00% | 0.0% |
Q2 2017 | $997,000 | +67.6% | 36,751 | +84.0% | 0.00% | 0.0% |
Q1 2017 | $595,000 | +27.1% | 19,968 | +15.8% | 0.00% | 0.0% |
Q4 2016 | $468,000 | +32.2% | 17,249 | +24.9% | 0.00% | 0.0% |
Q3 2016 | $354,000 | +35.1% | 13,814 | -2.8% | 0.00% | – |
Q2 2016 | $262,000 | +85.8% | 14,212 | +91.0% | 0.00% | – |
Q1 2016 | $141,000 | -7.8% | 7,440 | +30.8% | 0.00% | – |
Q4 2015 | $153,000 | – | 5,687 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |